FDA has approved AKEEGA (niraparib and abiraterone) as the first precision therapy for BRCA2+ metastatic castration-sensitive ...
Presented at 2025 SABCS, the phase III lidERA trial showed that oral SERD giredestrant reduced the risk of invasive disease ...
The Phase 3 MajesTEC 3 trial showed that teclistamab plus daratumumab reduced the risk of progression or death by 83% and ...
One in four patients with HR+ HER2- metastatic breast cancer remained progression free for at least four years with Kisqali ...
Preoperative radiation improved T-cell infiltration in patients with HR+ HER2- breast cancer when administered in combination ...
GSK’s B7-H3 targeted antibody drug conjugate risvutatug rezetecan has received FDA Orphan Drug Designation for small cell ...
The results from HER2CLIMB-05 study, presented at the 2025 SABCS annual meeting, demonstrated that tucatinib (TUKYSA) added ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback